Effectiveness of HPV vaccines in real-world study
10.3760/cma.j.cn112309-20221018-00343
- VernacularTitle:HPV疫苗有效性的真实世界研究
- Author:
Kongxin ZHU
1
;
Qi CHEN
;
Xiaowen HU
;
Yue HUANG
;
Yingying SU
;
Ting WU
Author Information
1. 厦门大学公共卫生学院，国家传染病诊断试剂与疫苗工程技术研究中心，分子疫苗学和分子诊断学国家重点实验室，医用生物制品省部共建协同创新中心，厦门 361102
- Keywords:
Human papillomavirus;
Vaccine;
Real-world study;
Effectiveness
- From:
Chinese Journal of Microbiology and Immunology
2023;43(3):230-238
- CountryChina
- Language:Chinese
-
Abstract:
Human papillomavirus (HPV) is an epitheliotropic virus. High-risk HPV infections lead to precancerous lesions which may progress to cancer in the cervix, vagina and vulva, while low-risk HPV infections cause benign lesions such as genital warts and recurrent respiratory papillomas. HPV infection remains one of the major public health problems threatening human health. To date, six prophylactic preventive HPV vaccines have been licensed, and the effectiveness of HPV vaccination has gradually appeared in some countries with earlier vaccination. HPV vaccination has been proved to be effective in protecting against diseases related to HPV infection, which leads to significant reductions in the incidence of vaccine-type HPV-related infection, high cervical lesions, anogenital warts, recurrent respiratory papillomatosis and other relevant diseases. The herd protection effect of the vaccines is outstanding. Meanwhile, a bivalent HPV vaccine has been demonstrated for the cross-protection against HPV infections of non-vaccine types (HPV31/33/45) in real-world vaccination practice.
